The present invention provides a method of manufacturing circular nucleic acid vectors containing a transgene comprising: (a) contacting a host system with a template, wherein the template comprises at least one flanking cleavage site(s), and (i) at least one phage origin of replication (ORI); (ii) at least one Terminal Repeat (TR), and; (iii) a promoter sequence operatively linked to a transgene; (b) incubating the host system for a time sufficient for replication to occur resulting in circular nucleic acid production; and (c) recovering the circular nucleic acid production, wherein the circular nucleic acid self-anneals.

Novel chimeric proteins may be used to inhibit transcriptional A activities that are mediated by transcription factor interactions with P-TEFb. The chimeras contain elements that recruit the target transcription factor, maintain CDK9 in an inactive state, and competitively inhibit P-TEFb binding to the transcription factor. The chimeras may be configured for inhibition of HIV Tat mediated transcription and thus provide a novel means of preventing reactivation of integrated HIV, providing a new tool for emerging “block and lock” HIV cure strategies.

Provided are amino acid sequences capable of binding to and inhibiting a Cas protein's ability to bind to a nucleic acid molecule, thereby inhibiting the Cas protein's function in genome editing. Such Cas protein inhibitors, which can be comprised of a major coat protein (G8P), an extracellular region of the G8P (G8P.sub.EX), or a biological equivalent, are useful in improving the specificity of Cas protein-based genome editing procedures.

The present invention provides for a modified virus, such as a recombinant M13 phage, which in an array, such as a film, is capable of producing piezoelectricity. The modified virus comprises a coat protein can displays a negatively charged amino acid sequence. The present invention provides for a device comprising a piezoelectric element comprising a suitable virus, such as the modified virus, a first surface and a second surface, wherein the first surface is in contact with a first electrode and the second surface is in contact with a second electrode, wherein when pressure is applied to the film, the film is capable of generating an electric current. The present invention provides for a method of making the device, and a method for generating electricity using the device.

The present invention relates to vectors suitable for use in displaying proteins on the surface of bacteriophage M13 as fusion constructs with the surface protein P.III, bacteriophage M13 particles comprising a mutated P.III protein on the phage coat surface, as well as methods for producing bacteriophage M13 particles and methods for transfecting or infecting a host cell comprising the vectors and bacteriophage of the invention.

The present invention relates to variants of the general amyloid interaction motif (GAIM) of bacteriophage gene 3 protein (g3p) and fusion proteins thereof. The GAIM variants and fusion proteins of the invention are partially or fully deimmunized and demonstrate superior binding and specificity to a diverse array of amyloid proteins, and exhibit enhanced amyloid remodeling and inhibition of amyloid aggregation. The present invention further relates to nucleic acids, vectors, host cells, and methods of making the GAIM variants and fusion proteins thereof. The present invention also relates to pharmaceutical compositions and methods of increasing bacteriophage infectivity, methods of detecting amyloid aggregates, and methods of diagnosing and/or treating a disease associated with misfolded and/or aggregated amyloid protein.

Disclosed herein are novel synthetic bacteriophages and bacteriophage compositions, methods of production thereof, and therapeutic uses thereof.

The present disclosure relates to a composition for detecting a potato virus Y including an M13KO7 bacteriophage and a kit including the same. Since the M13KO7 bacteriophage of the present disclosure may be easily produced using E. coli and is a large aggregate of proteins, the M13KO7 bacteriophage is more stable than antibodies even when exposed to external physical or chemical factors. Therefore, the composition of the present disclosure has an effect of diagnosing only the PVY specifically and accurately and may be usefully used in related industries.

Provided are engineered phages populations, which are homogeneous in length, as well as methods of making and methods of using such phages. Also provided are engineered chlorotoxin-phages as well as their methods of making and using. The disclosed homogeneous phage populations and chlorotoxin-phages may be used, for example, for treating and/or imaging tumors, such as central nervous system tumors.

The present disclosure relates to a method of in vitro engineering of nucleic acids. This disclosure further relates to in vitro engineering of viral genomes and to the improvement of viral properties by in vitro genomic engineering of viral genomes. Specifically, the disclosure relates to in vitro viral genomic digestion using RNA-guided Cas9, the assembly of a recombinant genome by the insertion of a DNA or RNA fragment into the digested viral genome and transformation of a host cell with the recombinant genome. This method also related to in vitro engineering for error correction of nucleic acids.